PTAB Upholds Validity of BMS Patent


The PTAB issued a Final Written Decision upholding the validity of Bristol-Myers Squibb’s U.S. Patent 8,476,239, which had been challenged by Momenta in IPR2015-01537.  According to documents filed with the PTAB during the IPR, the ‘239 patent covers stable formulations of a protein called “CTLA4Ig.”  This protein is sold by BMS under the  tradename Orencia® (abatacept), which is approved to treat rheumatoid arthritis.

Selected documents related to this and other IPRs concerning biologic patents can be found on our IPR tracker page.

Download PDF

Tagged with 

Comments are closed.